The first ever FDA-approved cannabis-derived product came a step nearer reality when an independent panel at the agency recommended it as a “safe” and “efficacious” treatment for childhood seizures ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.